| Q27025112 | Biomarkers for ectopic pregnancy and pregnancy of unknown location |
| Q44818655 | First trimester levels of inhibins and activin A in normal and failing pregnancies |
| Q24815419 | Follicular fluid levels of vascular endothelial growth factor and early corpus luteum function during assisted reproductive technology cycles |
| Q28308094 | GnRH agonist for triggering of final oocyte maturation: time for a change of practice? |
| Q34554500 | Human embryo implantation: current knowledge and clinical implications in assisted reproductive technology |
| Q34204531 | Inhibin at 90: from discovery to clinical application, a historical review |
| Q35064307 | Inhibins and activins: clinical advances in reproductive medicine |
| Q37144880 | Inhibins as diagnostic markers in human reproduction |
| Q79302351 | Inhibins, activins and anti-Müllerian hormone: structure, signalling pathways, roles and predictive value in reproductive medicine |
| Q46972538 | Maternal serum hormone concentrations for prediction of adverse outcome in threatened miscarriage |
| Q34307711 | Measurement of inhibin A and activin A in pregnancy--possible diagnostic applications |
| Q63359716 | Measurement of inhibin A and inhibin pro-αC in early human pregnancy and their role in the prediction of pregnancy outcome in patients with recurrent pregnancy loss |
| Q35925820 | Serum biomarkers for predicting pregnancy outcome in women undergoing IVF: human chorionic gonadotropin, progesterone, and inhibin A level at 11 days post-ET. |
| Q35553694 | The TGF-β Superfamily and Its Roles in the Human Ovary and Placenta |